EDITORIAL BOARD MEMBERS
Department of Nephrology and Hypertension
Vanderbilt University School of Medicine
Dr. Gerald Schulman has been involved in clinical trials at Vanderbilt University for over two decades and I serve as the co-director of the Clinical Trials Center at Vanderbilt (CTC). He was one of the investigators who participated in designing then HEMO Study and the AASK Study. He was a co-investigator in the MDRD (Phase III) and AASK studies and I was the principal investigator from Vanderbilt for the HEMO Study.
He has participated or led studies in this area. His efforts include with ESA, novel substances to prevent progression of CKD (He designed and was Chair of the Steering Committee for the EPPIC Study examining the effect of AST-120 on progression of CKD), the use of angiotens in receptor blockers in preventing progression of CKD and participation in the Frequent Dialysis Network.
The CTC of the nephrology division is poised to be able to design trials in patients evaluating interventions with CKD.